Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Molecular Cancer Research : MCR|February 12, 2024
Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived XenograftsZoi E Sychev, Abderrahman Day, Hannah E Bergom, et al.
Biorxiv : the Preprint Server for Biology|August 14, 2023
Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived XenograftsZoi E Sychev, Abderrahman Day, Hannah E Bergom, et al.
Cancer Research Communications|August 8, 2024
MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate CancerBeatriz German, Sarah A Alaiwi, Kun-Lin Ho, et al.
Cancer Research|March 5, 2020
<i>ATM</i> Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate CancerShahrzad Rafiei, Kenyon Fitzpatrick, David Liu, et al.
Cancer Immunology Research|February 27, 2026
Integrated Single-Cell Profiling Reveals Dichotomous NK Cell Populations Associated with Immunosuppression in Solid TumorsJohn R Lozada, Atef Ali, Christine Luo, et al.
Prostate Cancer and Prostatic Diseases|October 26, 2025
HLA class I expression shapes the tumor immune microenvironment and influences prognosis in prostate cancerPornlada Likasitwatanakul, Carissa Besonen, Alexander K Tsai, et al.
The Oncologist|March 5, 2026
Molecular Landscape of Prostate Cancers with Clival MetastasesPornlada Likasitwatanakul, Steven M Blinka, Jabra G Zarka, et al.
Developmental Cell|January 6, 2022
YAP1 and PRDM14 converge to promote cell survival and tumorigenesisMiju Kim, Seav Huong Ly, Yingtian Xie, et al.
Cell Reports. Medicine|April 21, 2026
Plasma extracellular vesicle proteomics nominates candidate biomarkers of <sup>177</sup>Lu-PSMA-617 outcomes in metastatic prostate cancer patientsAli T Arafa, Ella Boytim, Megan L Ludwig, et al.
Cancer Research Communications|January 28, 2025
Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic TargetingJohn R Lozada, Andrew Elliott, Mark G Evans, et al.
Pageof 4